SEC Comment Letter for Avalo Therapeutics, (AVTX) — Jan 14, 2026
Avalo Therapeutics, Inc.
Date: Jan. 14, 2026 · CIK: 0001534120 · Accession: 0000000000-26-000493
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-292614
Letter
Re: Avalo Therapeutics, Inc. Registration Statement on Form S-3 Filed January 8, 2026 File No. 333-292614 Dear Garry Neil:
January 14, 2026
Garry Neil Chief Executive Officer Avalo Therapeutics, Inc. 1500 Liberty Ridge Drive, Suite 321 Wayne, PA 19087
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Jennifer Porter
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> January 14, 2026 Garry Neil Chief Executive Officer Avalo Therapeutics, Inc. 1500 Liberty Ridge Drive, Suite 321 Wayne, PA 19087 Re: Avalo Therapeutics, Inc. Registration Statement on Form S-3 Filed January 8, 2026 File No. 333-292614 Dear Garry Neil: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Jennifer Porter </TEXT> </DOCUMENT>